VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC:ISOLD) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD
innovator and market leader specializing in the development of pharmaceutical drug deliveries, health and wellness products and now
supporting the pharmaceutical industry at large with BSPG Laboratories, LTD. recently approved CBD as an Active Pharmaceutical
Ingredient, is pleased to announce it has signed a letter of intent with Toronto based Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) (“Pure Global”), for
the ongoing supply of pharmaceutical and nutraceutical grade Cannabidiol (CBD) isolates and other potential products.
Pure Global is a vertically integrated, growth-oriented life sciences cannabis company led by experienced pharma industry,
horticultural, and supply chain experts. The Company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under
Canada’s Access to Cannabis for Medical Purposes Regulations ("ACMPR").
Upon the successful importation and product testing of an initial trial order of raw CBD isolate, Pure Global and Isodiol intend
to establish a Definitive Supply Agreement for the ongoing supply of CBD isolate and intend to explore additional means of
collaborating together.
Marcos Agramont, CEO of Isodiol, stated: “Pure Global’s team is comprised of passionate pharma-industry leaders whose vision is
to utilize leading-edge pharmaceutical technologies and harness the therapeutic properties of world-class cannabidiol ( CBD ) based
products. We look forward to this new partnership to supply BSPG Labs’ industry leading pharmaceutical grade CBD designated as an
Active Pharmaceutical Ingredient.”
“We’re excited to secure this pharmaceutical grade source of U.K. manufactured CBD from Isodiol and BSPG Labs at a time when new
local British and regional European opportunities are presenting themselves by the day,” said Pure Global President & CEO, Malay
Panchal. “Notwithstanding the growing demand for CBD in Canada and our plans for pharma and nutra grade imports, we call ourselves
‘Global’ for a reason. This is the first of a number of strategic initiatives which will help propel our international vision
forward.”
As a GMP certified facility, Isodiol’s subsidiary BSPG Laboratories Ltd. has received government approval from the United
Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI
2012/1916), for the manufacturing of CBD under certificate number: UK API 48727.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade pure,
natural CBD and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural
isolated CBD, micro-encapsulations, and nano-technology for the highest quality consumable and topical skin care products. Most
recently, the company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished
Pharmaceutical Products as was announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its
consumer products portfolio and aggressively continue international expansion into Latin America, Asia, and Europe.
Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
Twitter: @Isodiolintlinc
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking
statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the
forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.
